Related Experiment Video

Updated: Mar 12, 2026

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.2K

Graphene Oxide-Gallic Acid Nanodelivery System for Cancer Therapy

Dena Dorniani1,2, Bullo Saifullah2, Farahnaz Barahuie2,3

  • 1Department of Chemistry, University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK.

Nanoscale Research Letters
|November 9, 2016
PubMed

Insights

This study developed a graphene oxide (GO) and gallic acid (GA) nanocomposite (GOGA) for targeted cancer therapy. The GOGA system effectively inhibited liver cancer cell growth while sparing normal cells.

Area of Science:

  • Biomedical Science
  • Nanotechnology
  • Materials Science

Background:

  • Cancer remains a significant global health challenge despite advances in biomedical science.
  • Developing effective and targeted drug delivery systems is crucial for improving cancer treatment outcomes.
  • Graphene oxide (GO) offers potential as a nanocarrier due to its unique properties.

Purpose of the Study:

  • To design and characterize a novel anticancer nanodelivery system using graphene oxide (GO) as a carrier for gallic acid (GA).
  • To evaluate the in vitro efficacy of the developed gallic acid-graphene oxide nanocomposite (GOGA) against liver cancer cells.

Main Methods:

  • Synthesis and characterization of the gallic acid-graphene oxide nanocomposite (GOGA) using techniques like XRD, FTIR, HRTEM, Raman, and UV/Vis spectroscopy.
  • In vitro release studies of gallic acid from the GOGA nanocomposite in phosphate-buffered saline (PBS) at pH 7.4.
  • In vitro cytotoxicity assays using normal fibroblast (3T3) and liver cancer cells (HepG2) treated with GO, GOGA, and GA.

Main Results:

  • The GOGA nanocomposite was successfully synthesized and characterized.
  • Sustained release of gallic acid from the GOGA nanocomposite was observed at physiological pH (7.4).
  • The GOGA nanocomposite demonstrated significant inhibition of liver cancer cell (HepG2) growth without adversely affecting normal fibroblast cells (3T3).

Conclusions:

  • The developed GOGA nanocomposite is a promising targeted anticancer nanodelivery system.
  • This system exhibits selective toxicity towards cancer cells, highlighting its therapeutic potential.
  • Further in vivo studies are warranted to explore the full therapeutic capabilities of the GOGA nanocomposite.
Keywords:
Controlled-releaseCytotoxicityDrug delivery systemsGallic acidGraphene oxide

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.6K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.8K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
161
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K